Ascendis Pharma CEO tight-lipped on potential assault on Novo Nordisk's mother lode
![Jessica Hill/AP/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/14835282/pfyczg/ALTERNATES/schema-16_9/20072641058025-5400x3600ma.jpg)
The prospects of winning even a thin slice of the rapidly growing – and extremely lucrative – market for GLP-1 drugs for the treatment of type 2 diabetes, obesity, and more should appeal to most pharma leaders.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk ready to go toe to toe with Ascendis
For subscribers